Trial · NCT01058239
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 21
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leukocytosis | Blood and lymphatic system disorders | Rituximab Plus Bortezomib | 2 | 7 | 3 |
| other | Cardiac arrest | Cardiac disorders | Rituximab Plus Bortezomib | 1 | 7 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Rituximab Plus Bortezomib | 1 | 7 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Rituximab Plus Bortezomib | 1 | 7 | 1 |
| other | Nausea | Gastrointestinal disorders | Rituximab Plus Bortezomib | 1 | 7 | 2 |
| other | Catheter related infection | Infections and infestations | Rituximab Plus Bortezomib | 1 | 7 | 1 |
| other | Lung infection | Infections and infestations | Rituximab Plus Bortezomib | 1 | 7 | 1 |
| other | Lymphocyte count decreased | Investigations | Rituximab Plus Bortezomib | 4 | 7 | 19 |
| other | Neutrophil count decreased | Investigations | Rituximab Plus Bortezomib | 7 | 7 | 38 |
| other | Platelet count decreased | Investigations | Rituximab Plus Bortezomib | 7 | 7 | 37 |
| other | Alkaline phosphatase increased | Investigations | Rituximab Plus Bortezomib | 1 | 7 | 4 |
| other | Anorexia | Metabolism and nutrition disorders | Rituximab Plus Bortezomib | 1 | 7 | 1 |
| other | Aspartate aminotransferase increased | Investigations | Rituximab Plus Bortezomib | 1 | 7 | 1 |
| other | Hyperkalemia | Metabolism and nutrition disorders | Rituximab Plus Bortezomib | 1 | 7 | 2 |
| other | Hyponatremia | Metabolism and nutrition disorders | Rituximab Plus Bortezomib | 2 | 7 | 6 |
| other | Peripheral motor neuropathy | Nervous system disorders | Rituximab Plus Bortezomib | 7 | 7 | 37 |
| other | Peripheral sensory neuropathy | Nervous system disorders | Rituximab Plus Bortezomib | 7 | 7 | 37 |
| other | Urinary tract pain | Renal and urinary disorders | Rituximab Plus Bortezomib | 1 | 7 | 1 |
| serious | Platelet count decreased | Investigations | Rituximab Plus Bortezomib | 1 | 7 | 1 |
| serious | Lymphocyte count decreased | Investigations | Rituximab Plus Bortezomib | 1 | 7 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01058239/events